Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Preliminary studies suggested that delta-9-tetrahydrocannabinol (THC), the major psychoactive ingredient of Cannabis sativa L., might be effective in the treatment of Tourette syndrome (TS). This study was performed to investigate for the first time under controlled conditions, over a longer-term treatment period, whether THC is effective and safe in reducing tics in TS. Method In this randomized, double-blind, placebo-controlled study, 24 patients with TS, according to DSM-III-R criteria, were treated over a 6-week period with up to 10 mg/day of THC. Tics were rated at 6 visits (visit 1, baseline; visits 2-4, during treatment period; visits 5-6, after withdrawal of medication) using the Tourette Syndrome Clinical Global Impressions scale (TS-CGI), the Shapiro Tourette-Syndrome Severity Scale (STSSS), the Yale Global Tic Severity Scale (YGTSS), the self-rated Tourette Syndrome Symptom List (TSSL), and a videotape-based rating scale. Results Seven patients dropped out of the study or had to be excluded, but only 1 due to side effects. Using the TS-CGI, STSSS, YGTSS, and video rating scale, we found a significant difference (p Conclusion Our results provide more evidence that THC is effective and safe in the treatment of tics. It, therefore, can be hypothesized that the central cannabinoid receptor system might play a role in TS pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,064
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M., & Piomelli, D. (1999) · Nature Neuroscience · doi:10.1038/7268 · Cited by 775
Tourette syndrome, associated conditions and the complexities of treatment
Robertson, M. M. (2000) · Brain · doi:10.1093/brain/123.3.425 · Cited by 704
CB1 Cannabinoid Receptor Inhibits Synaptic Release of Glutamate in Rat Dorsolateral Striatum
Gerdeman, G., & Lovinger, D. M. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.85.1.468 · Cited by 433
A Functional Neuroanatomy of Tics in Tourette Syndrome
Stern, E., Silbersweig, D. A., Chee, K.-Y., Holmes, A., Robertson, M. M., Trimble, M., Frith, C. D., Frackowiak, R. S. J., & Dolan, R. J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.741 · Cited by 333
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Russo, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30401-8 · Cited by 564
“The two identified, small RCTs for Tic/Tourette syndrome compared pharmaceutical THC:CBD with placebo amongst participants with Tic/Tourette syndrome 43,70 .”
(2014) · Neurology · doi:10.1212/wnl.0000000000000363 · Cited by 553
“In a Class III placebo-controlled study of tics in 24 patients, patients received up to 10 mg/d of THC orally over 6 weeks.(40) After Bonferroni correction, there were no significant differences.”
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
“However, only two controlled trials have investigated its efficacy in the treatment of this syndrome (605, 607), and they reported effectiveness against tics but no improvement of neuropsychological performance.”
BackgroundAizpurua-Olaizola, O., Soydaner, U., Öztürk, E., Schibano, D., Simsir, Y., Navarro, P., Etxebarria, N., & Usobiaga, A. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00949 · Cited by 467
the ESSTS Guidelines Group, Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., Skov, L., Strand, G., Stern, J. S., Termine, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0163-7 · Cited by 461
“Tetrahydrocannabinol (THC) has been suggested to be effective and safe in the treatment of tics [162–164] without influence on neuropsychological performance [161].”
BackgroundTourette's syndrome: from behaviour to biology
Singer, H. S. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)01012-4 · Cited by 309
The Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
Cannabinoids in Clinical Practice
Williamson, E. M., & Evans, F. J. (2000) · Drugs · doi:10.2165/00003495-200060060-00005 · Cited by 283
Baron, E. P. (2018) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 251
Pringsheim, T., Holler-Managan, Y., Okun, M. S., Jankovic, J., Piacentini, J., Cavanna, A. E., Martino, D., Müller-Vahl, K., Woods, D. W., Robinson, M., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007467 · Cited by 252
Reliability and validity of the Yale Global Tic Severity Scale.
Storch, E. A., Murphy, T. K., Geffken, G. R., Sajid, M., Allen, P., Roberti, J. W., & Goodman, W. K. (2005) · Psychological Assessment · doi:10.1037/1040-3590.17.4.486 · Cited by 257
Weisman, H., Qureshi, I. A., Leckman, J. F., Scahill, L., & Bloch, M. H. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.09.008 · Cited by 237
Cannabinoids in health and disease
Kogan, N. M., & Mechoulam, R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/nkogan · Cited by 222
Baron, E. P. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12570 · Cited by 206
Canadian Guidelines for the Evidence-Based Treatment of Tic Disorders: Pharmacotherapy
Pringsheim, T., Doja, A., Gorman, D., McKinlay, D., Day, L., Billinghurst, L., Carroll, A., Dion, Y., Luscombe, S., Steeves, T., et al. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700302 · Cited by 191
Roessner, V., Eichele, H., Stern, J. S., Skov, L., Rizzo, R., Debes, N. M., Nagy, P., Cavanna, A. E., Termine, C., Ganos, C., et al. (2022) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-021-01899-z · Cited by 197
“No serious adverse reactions were reported either, with only mild adverse reactions including dizziness, tiredness, and dry mouth [160, 161].”
BackgroundDelta-9-tetrahydrocannabinol for nighttime agitation in severe dementia
Walther, S., Mahlberg, R., Eichmann, U., & Kunz, D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0343-1 · Cited by 189
“In a recent study on the use of dronabinol in patients with Tourette’s syndrome, no influence on neuropsychological function was observed (Muller-Vahl et al. 2003a).”
BackgroundMethodGonçalves, J., Rosado, T., Soares, S., Simão, A. Y., Caramelo, D., Luís, Â., Fernández, N., Barroso, M., Gallardo, E., & Duarte, A. P. (2019) · Medicines · doi:10.3390/medicines6010031 · Cited by 189
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Constituents of Cannabis Sativa
Rock, E. M., & Parker, L. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_1 · Cited by 210
European clinical guidelines for Tourette Syndrome and other tic disorders
Roessner, V., Rothenberger, A., Rickards, H., & Hoekstra, P. J. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0165-5 · Cited by 171
Plant, Synthetic, and Endogenous Cannabinoids in Medicine
Marzo, V. D., & Petrocellis, L. D. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.011205.135648 · Cited by 169
Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders
Fernández‐Ruiz, J., Hernández, M., & Ramos, J. A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00144.x · Cited by 163
“However, in some cases, a few number of clinical trials have been already conducted unfortunately with poorly effective results [83–88].”
ResultLim, K., See, Y. M., & Lee, J. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.4.301 · Cited by 166
Medical Cannabinoids in Children and Adolescents: A Systematic Review
Wong, S. S., & Wilens, T. E. (2017) · PEDIATRICS · doi:10.1542/peds.2017-1818 · Cited by 172
Treatment strategies for tics in Tourette syndrome
Eddy, C. M., Rickards, H. E., & Cavanna, A. E. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610390261 · Cited by 158
Pharmacological treatment of tic disorders and Tourette Syndrome
Roessner, V., Schoenefeld, K., Buse, J., Bender, S., Ehrlich, S., & Münchau, A. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.043 · Cited by 149
Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome
Quezada, J., & Coffman, K. A. (2018) · CNS Drugs · doi:10.1007/s40263-017-0486-0 · Cited by 144
“It did demonstrate significant reduction in tics, without significant side effects [65].”
BackgroundCannabis Therapeutics and the Future of Neurology
Russo, E. B. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00051 · Cited by 131
“…al., 2007; Babson et al., 2017), glaucoma (Merritt et al., 1980), lower urinary tract symptoms (LUTS; Brady et al., 2004; Kavia et al., 2010), social anxiety (Bergamaschi et al., 2011), Tourette syndrome (Müller-Vahl et al., 2002, 2003) and schizophrenia (Leweke et al., 2012; McGuire et al., 2018).”
BackgroundTargeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors
van Egmond, N., Straub, V. M., & van der Stelt, M. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-112741 · Cited by 122
“In addition, cannabis-basedmedicines have been associated with positive results in Tourette’s syndrome (29, 30) and in levodopa-induced dyskinesia in Parkinson’s disease (31).”
BackgroundTreatment of tics and Tourette syndrome
Singer, H. S. (2010) · Current Treatment Options in Neurology · doi:10.1007/s11940-010-0095-4 · Cited by 97
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00984-4 · Cited by 131
Singer, H. S. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000752 · Cited by 139
The therapeutic potential of cannabinoids for movement disorders
Kluger, B., Triolo, P., Jones, W., & Jankovic, J. (2015) · Movement Disorders · doi:10.1002/mds.26142 · Cited by 122
Anggadiredja, K., Nakamichi, M., Hiranita, T., Tanaka, H., Shoyama, Y., Watanabe, S., & Yamamoto, T. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300454 · Cited by 127
“Indeed, this mechanism might underlie the ameliorating effect of cannabinoid activation in animal models (Beltramo et al, 2000) as well as the patients (Muller-Vahl et al, 2003) of disorders related to the hyperactive dopaminergic tone.”
BackgroundCurrent Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments
Billnitzer, A., & Jankovic, J. J. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00914-6 · Cited by 134
Is the Party Over? Cannabis and Juvenile Psychiatric Disorder: The Past 10 Years
Rey, J. M., Martin, A., & Krabman, P. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000135623.12843.60 · Cited by 136
“Controlled study data from one group suggest that THC may be effective in Tourette’s disorder (Muller-Vahl et al., 2003).”
BackgroundCannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia
García, C., Palomo‐Garo, C., Gómez‐Gálvez, Y., & Fernández‐Ruíz, J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13215 · Cited by 123
“However, the few clinical trials conducted so far have not revealed many positive results (Frankel et al., 1990; Sieradzan et al., 2001; Fox et al., 2002; Müller-Vahl et al., 2002; 2003; Jabusch et al., 2004; Mesnage et al., 2004; Fabbrini et al., 2007).”
BackgroundShprecher, D., & Kurlan, R. (2009) · Movement Disorders · doi:10.1002/mds.22378 · Cited by 127
Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
Turna, J., Patterson, B., & Van Ameringen, M. (2017) · Depression and Anxiety · doi:10.1002/da.22664 · Cited by 100
“5–10mg/dayof THC,where a significant reduction in tic severity and motor tic intensity on the Tourette’s Syndrome Global Impressions Scalewas found compared to placebo (P= .008 and .05, respectively) (Müller-Vahl et al., 2003).”
MethodTreatment of Tourette Syndrome with Cannabinoids
Müller-Vahl, K. R. (2013) · Behavioural Neurology · doi:10.1155/2013/294264 · Cited by 101
Cannabis and Its Derivatives: Review of Medical Use
Leung, L. (2011) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2011.04.100280 · Cited by 102
Sevy, S. M., Robinson, D. G., Napolitano, B. A., Patel, R. C., Gunduz‐Bruce, H., Miller, R., McCormack, J., Lorell, B. S., & Kane, J. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.037 · Cited by 109
Effects of Δ9-Tetrahydrocannabinol on Human Working Memory Function
Bossong, M. G., Jansma, J. M., van Hell, H. H., Jager, G., Oudman, E., Saliasi, E., Kahn, R. S., & Ramsey, N. F. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.01.008 · Cited by 103
Cannabinoids for Tourette's Syndrome
Curtis, A., Clarke, C. E., & Rickards, H. E. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006565.pub2 · Cited by 88
Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Deik, A., Saunders-Pullman, R. J., & Luciano, M. S. (2012) · Current Drug Abuse Reviews · doi:10.2174/1874473711205030243 · Cited by 91
“Interestingly, cannabinoids have been studied in the management of different neurologic conditions, with varying degrees of success: they have been approved in Germany for the treatment of spasticity in multiple sclerosis, [83] have been found not to be different than placebo in the management of chorea in Huntington’…”
BackgroundA Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications
Wilkinson, S. T., Radhakrishnan, R., & D’Souza, D. C. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15r10036 · Cited by 88
Trials of Pharmacological Interventions for Tourette Syndrome: A Systematic Review
Waldon, K., Hill, J., Termine, C., Balottin, U., & Cavanna, A. E. (2013) · Behavioural Neurology · doi:10.1155/2013/626410 · Cited by 88
Mcguire, J. F., Kugler, B. B., Park, J. M., Horng, B., Lewin, A. B., Murphy, T. K., & Storch, E. A. (2012) · Child Psychiatry & Human Development · doi:10.1007/s10578-012-0300-7 · Cited by 82
“The STSSS has demonstrated treatment sensitivity to pharmacological treatments [88, 90].”
BackgroundHuman Studies of Cannabinoids and Medicinal Cannabis
Robson, P. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_25 · Cited by 94
Dzierżanowski, T. (2019) · Cancers · doi:10.3390/cancers11020129 · Cited by 84
“THC significantly reduces the severity of tics and obsessive-compulsive disorder in patients with Tourette syndrome [88,89].”
BackgroundMedical marijuana and the developing role of the pharmacist
Seamon, M. J., Fass, J. A., Maniscalco-Feichtl, M., & Abu-Shraie, N. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060471 · Cited by 82
“Marijuana is also used in the treatment of various movement disorders including dystonia, Parkinson’s disease, Huntington’s disease, and tics associated with Tourette’s syndrome.(19) Marijuana is also used to prevent seizures in patients with epilepsy and is believed to have neuroprotective properties.”
BackgroundMedicinal Uses of Marijuana and Cannabinoids
Grotenhermen, F., & Müller‐Vahl, K. (2016) · Critical Reviews in Plant Sciences · doi:10.1080/07352689.2016.1265360 · Cited by 88
“A doubleblind placebo-controlled study with 24 patients was conducted at the Hannover Medical School, Germany (M€uller-Vahl et al., 2003).”
MethodCannabinoids reduce symptoms of Tourette’s syndrome
Müller-Vahl, K. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.10.1717 · Cited by 74
Tourette disorder and other tic disorders
Deeb, W., Malaty, I. A., & Mathews, C. A. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00008-3 · Cited by 73
Treatment-refractory Tourette Syndrome
Kious, B. M., Shahed, J. J., & Shprecher, D. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.003 · Cited by 71
“A parallel study demonstrated that THC in the above doses did not have a significant effect on learning curve, interference, recall and recognition of word lists, immediate visual memory span, verbal memory span, or divided attention.”
BackgroundInfluentialPreliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome
Abi‐Jaoude, E., Chen, L., Cheung, P., Bhikram, T., & Sandor, P. (2017) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.16110310 · Cited by 71
“This would be much higher than the up to 10 mg used in the previous trials with oral THC.”
MethodResultInfluentialTourette syndrome and other chronic tic disorders: an update on clinical management
Martino, D., & Pringsheim, T. M. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1413938 · Cited by 66
“The efficacy of tetrahydrocannabinol has been assessed with two small randomized controlled trials versus placebo [80,92], with one trial being a single-dose study [80].”
MethodPharmacological Options for the Treatment of Tourette??s Disorder
Jim??nez-Jim??nez, F. J., & Ruiz, P. (2001) · Drugs · doi:10.2165/00003495-200161150-00005 · Cited by 62
Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12‐Week, Randomized, Controlled Study
Müller‐Vahl, K., Fremer, C., Beals, C. R., Ivkovic, J., Loft, H., & Schindler, C. (2021) · Movement Disorders · doi:10.1002/mds.28681 · Cited by 63
Hasan, A., Rothenberger, A., Münchau, A. M., Wobrock, T., Falkai, P., & Roessner, V. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d236ec · Cited by 64
“This decision was guided by the patients’ experience of tremendous decrease of inner tension and tic severity when he had smoked marihuana illegally and reports of the usefulness of $9-THC to treat tics in the literature.(7) The patient reported that he has started illicit marihuana use at the age of 13 years.”
BackgroundSzejko, N., & Müller‐Vahl, K. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s251499 · Cited by 63
Sidlo, Z., Reggio, P. H., & Rice, M. E. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.07.014 · Cited by 64
“Furthermore, the present findings suggest a physiological substrate for the clinically relevant observations that CB1R agonists can attenuate motor tics in Tourette's syndrome (Muller-Vahl et al., 2003) and DOPA-induced dyskinesia in a Parkinson's disease model (Sieradzan et al.”
BackgroundInfluentialThe Pharmacological History of Cannabis
Russo, E. B. (2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199662685.003.0002 · Cited by 67
Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience
Mostafavi, M., & Gaitanis, J. N. (2020) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2020.100833 · Cited by 63
Mato, S., & Pazos, Á. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.11.004 · Cited by 56
Clinical Pharmacokinetics of Cannabinoids
Grotenhermen, F. (2003) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n01_02 · Cited by 64
Berding, G., Müller-Vahl, K., Schneider, U., Gielow, P., Fitschen, J., Stuhrmann, M., Harke, H., Buchert, R., Donnerstag, F., Hofmann, M., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.005 · Cited by 54
Self-citationMilosev, L. M., Psathakis, N., Szejko, N., Jakubovski, E., & Müller‐Vahl, K. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0050 · Cited by 59
Behrenswerth, A., Volz, N., Toräng, J., Hinz, S., Bräse, S., & Müller, C. E. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.02.027 · Cited by 57
Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome
Müller‐Vahl, K., Bîndilă, L., Lutz, B., Mußhoff, F., Skripuletz, T., Baumgaertel, C., & Sühs, K. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0671-6 · Cited by 53
The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection: Present and Future
Martino, D., Deeb, W., Shahed, J. J., Malaty, I. A., Pringsheim, T. M., Fasano, A. A., Ganos, C., Wu, W., & Okun, M. S. (2021) · Neurology · doi:10.1212/wnl.0000000000011704 · Cited by 55
Muccioli, G. G., Wouters, J., Charlier, C., Scriba, G. K. E., Pizza, T., Pace, P. D., de Martino, P., Poppitz, W., Poupaert, J. H., & Lambert, D. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050484f · Cited by 50
Tourette Syndrome Treatment Updates: a Review and Discussion of the Current and Upcoming Literature
Frey, J., & Malaty, I. A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01177-8 · Cited by 55
Kanaan, A. S., Jakubovski, E., & Müller‐Vahl, K. (2017) · Brain Sciences · doi:10.3390/brainsci7050047 · Cited by 51
“Therefore, our results corroborate recent findings in further open uncontrolled case studies [7,8,20–23] and small controlled clinical trials [9,10] reporting beneficial effects of CBM such as cannabis and THC in this group of patients.”
BackgroundResultTourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene
Gadzicki, D., Müller‐Vahl, K., Heller, D., Ossege, S., Nöthen, M. M., Hebebrand, J., & Stuhrmann, M. (2004) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20159 · Cited by 45
Wilson, J., Dobson, O., Langcake, A., Mishra, P., Bryant, Z., Leung, J., Dawson, D., Graham, M., Teesson, M., Freeman, T. P., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00015-5 · Cited by 48
Evidence-based treatment of Tourette’s disorder and chronic tic disorders
Essoe, J. K.-Y., Grados, M. A., Singer, H. S., Myers, N. S., & Mcguire, J. F. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643236 · Cited by 46
“d-serine; riluzole; cannabidiol, tetrahydrocannabinol) [134,135].”
McKee, K. A., Hmidan, A., Crocker, C. E., Lam, R. W. M., Meyer, J. H., Crockford, D. N., Trépanier, A., Aitchison, K. J., & Tibbo, P. G. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.044 · Cited by 47
Emerging drugs in Tourette syndrome
Silay, Y. S., & Jankovic, J. J. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.365 · Cited by 45
“In a subsequent randomised, double-blind, placebo-controlled study, 24 patients with TS were treated over a 6-week period with up to 10 mg/day of tetrahydrocannabinol [133].”
MethodThe pharmacology of Tourette syndrome
Thomas, R., & Cavanna, A. E. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-0979-z · Cited by 46
“…on cannabinoids show no significant difference in neuropsychological performance on tasks involving learning, interference, recall and recognition of word lists, immediate visual memory span and divided attention, with actual improvement in immediate verbal memory span (Muller-Vahl et al. 2003b).”
BackgroundMethodImprovement in Refractory Obsessive Compulsive Disorder With Dronabinol
Schindler, F., Anghelescu, I. G., Regen, F., & Jockers-Scherübl, M. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07061016 · Cited by 43
Müller‐Vahl, K., Pisarenko, A., Szejko, N., Haas, M., Fremer, C., Jakubovski, E., Musil, R., Münchau, A. M., Neuner, I., Huys, D., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115135 · Cited by 47
Therapeutic use of medical Cannabis in neurological diseases: a clinical update
Hidding, U., Mainka, T., & Buhmann, C. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02719-1 · Cited by 45
“A meta-analysis—albeit only based on two small RCTs (Müller-Vahl et al. 2002, 2003)—could not demonstrate a significant effect of THC on tics in GTS (Black et al. 2019).”
MethodInfluentialMedical marijuana in neurology
Benbadis, S. R., Sanchez‐Ramos, J., Bozorg, A. M., Giarratano, M., Kalidas, K., Katzin, L. W., Robertson, D. S., Vu, T., Smith, A., & Zesiewicz, T. A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.985209 · Cited by 48
New Prospect for Cancer Cachexia: Medical Cannabinoid
Wang, J., Wang, Y., Tong, M., Pan, H., & Li, D. (2019) · Journal of Cancer · doi:10.7150/jca.28246 · Cited by 41
Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics
Koppel, B. S. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0376-4 · Cited by 41
Jakubovski, E., & Müller‐Vahl, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081739 · Cited by 41
“As his insurance company had refused coverage of therapy costs with nabiximols, less expensive treatment with medical cannabis (based on a permission by the German federal opium agency) was initiated at a dose of 0.1 g vaporized medical cannabis (Bedrocan®, Veendam, The Netherlands), containing 22% THC and 1% CBD) onc…”
BackgroundResultPandey, S., & Dash, D. (2019) · The Neurologist · doi:10.1097/nrl.0000000000000218 · Cited by 40
Animal models of obsessive compulsive disorder: recent findings and future directions
Hoffman, K. L. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.577772 · Cited by 40
The Potential of Cannabinoid-Based Treatments in Tourette Syndrome
Artukoglu, B. B., & Bloch, M. H. (2019) · CNS Drugs · doi:10.1007/s40263-019-00627-1 · Cited by 40
Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome
Szejko, N., Saramak, K., Lombroso, A., & Müller-Vahl, K. (2022) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0081 · Cited by 42
“Controlled trials using nabiximols (level 1b) Only recently, CANNA-TICS, a large multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase IIb study was initiated to investigate the efficacy and safety of a 13-week-treatment with nabiximols on tics and a large variety of psychiatric comorbiditie…”
BackgroundMethodMarijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy
Babayeva, M., Assefa, H., Basu, P., Chumki, S. R., & Loewy, Z. G. (2016) · Parkinson s Disease · doi:10.1155/2016/1279042 · Cited by 48
Metadata
- Authors
- Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Heinrich Heine University Düsseldorf (DE)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-04-15
- Volume
- 64
- Issue
- 4
- Pages
- 459-465
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1981252279
- Cited by
- 270
- References
- 29
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 13 · 2023: 17 · 2022: 27 · 2021: 15 · 2020: 20 · 2019: 15 · 2018: 12 · 2017: 10 · 2016: 12 · 2015: 11 · 2014: 6 · 2013: 5 · 2012: 10
- FWCI
- 16.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- delta-9-tetrahydrocannabinol, Tourette syndrome, tics, cannabis, tic reduction, drug safety, Tourette syndrome treatment
- MeSH terms
- Adolescent, Adult, Double-Blind Method, Drug Administration Schedule, Female, Tourette Syndrome, Humans, Male, Middle Aged, Personality Inventory, Placebos, Psychiatric Status Rating Scales, Receptors, Drug, Severity of Illness Index, Dronabinol, Treatment Outcome, Tics, Receptors, Cannabinoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.